Allergan introduces Saphris 2.5mg sublingual black-cherry flavored tablets in US.
M2 PHARMA-July 21, 2015-Allergan introduces Saphris 2.5mg sublingual black-cherry flavored tablets in US
(C)2015 M2 COMMUNICATIONS
Allergan, a global pharmaceutical company, has launched its Saphris (asenapine) 2.5mg sublingual (placed under the tongue) black-cherry flavoured tablets in pharmacies in the United States, it was reported yesterday.
The company received approval for the product from the US FDA in March 2015. The product is intended for the acute treatment of manic or mixed episodes associated with bipolar I disorder in paediatric patients aged 10 to 17 years. The approval for the product was based on data from a three-week monotherapy trial in 403 paediatric patients.
Allergan Global R&D executive vice-president, David Nicholson, said, 'The approval of the paediatric indication and the availability of Saphris 2.5mg tablets at pharmacies throughout the US means that children, teens and their physicians will have a new treatment option available for this complex disorder.'
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Jul 21, 2015|
|Previous Article:||ContraFect receives US Patent Number 9,034,322 from US Patent and Trademark Office.|
|Next Article:||Motif Bio receives Qualified Infectious Diseases Product designation for iclaprim.|